In its Q3 report, Teva reported EPS at $0.58, which showed a 14.7% year-over-year slump. Given the extreme volatility of Teva’s shares, its serious debt problem, and ongoing legal woes which are only …
More Why Long-Term Investors Should Avoid TEVA Stock Like the Plague Videos